{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:20Z","timestamp":1790391200387,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T00:00:00Z","timestamp":1369699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/nrclinonc.2013.83","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T10:32:12Z","timestamp":1369737132000},"page":"390-399","source":"Crossref","is-referenced-by-count":180,"title":["Paradoxical oncogenesis\u2014the long-term effects of BRAF inhibition in melanoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Geoffrey T.","family":"Gibney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna V.","family":"Fedorenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiran S. M.","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,28]]},"reference":[{"key":"BFnrclinonc201383_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K. T.  et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809\u2013819 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201383_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B.  et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201383_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild, A.  et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358\u2013365 (2012).","journal-title":"Lancet"},{"key":"BFnrclinonc201383_CR4","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag, G.  et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596\u2013599 (2010).","journal-title":"Nature"},{"key":"BFnrclinonc201383_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H.  et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954 (2002).","journal-title":"Nature"},{"key":"BFnrclinonc201383_CR6","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci, E.  et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305\u20132315 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201383_CR7","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura, E. T.  et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454\u20131457 (2003).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201383_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1056\/NEJMc0904160","volume":"361","author":"J Tol","year":"2009","unstructured":"Tol, J., Nagtegaal, I. D. & Punt, C. J. A. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98\u201399 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201383_CR9","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1158\/0008-5472.CAN-03-3433","volume":"64","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock, C.  et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338\u20132342 (2004).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201383_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bcp.2011.05.015","volume":"82","author":"IV Fedorenko","year":"2011","unstructured":"Fedorenko, I. V., Paraiso, K. H. & Smalley, K. S. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem. Pharmacol. 82, 201\u2013209 (2011).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrclinonc201383_CR11","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1158\/0008-5472.CAN-08-3201","volume":"69","author":"RM Klein","year":"2009","unstructured":"Klein, R. M. & Aplin, A. E. Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res. 69, 2224\u20132233 (2009).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201383_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1755-148X.2008.00491.x","volume":"21","author":"RA Cartlidge","year":"2008","unstructured":"Cartlidge, R. A.  et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res. 21, 534\u2013544 (2008).","journal-title":"Pigment Cell Melanoma Res."},{"key":"BFnrclinonc201383_CR13","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","volume":"102","author":"KH Paraiso","year":"2010","unstructured":"Paraiso, K. H.  et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724\u20131730 (2010).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201383_CR14","doi-asserted-by":"publisher","first-page":"6670","DOI":"10.1158\/0008-5472.CAN-09-4471","volume":"70","author":"Y Shao","year":"2010","unstructured":"Shao, Y. & Aplin, A. E. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 70, 6670\u20136681 (2010).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201383_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","volume":"19","author":"I Arozarena","year":"2011","unstructured":"Arozarena, I.  et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19, 45\u201357 (2011).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201383_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/1078-0432.CCR-07-1440","volume":"14","author":"NK Haass","year":"2008","unstructured":"Haass, N. K.  et al. The mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin. Cancer Res. 14, 230\u2013239 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201383_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature04304","volume":"439","author":"DB Solit","year":"2006","unstructured":"Solit, D. B.  et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358\u2013362 (2006).","journal-title":"Nature"},{"key":"BFnrclinonc201383_CR18","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.0711741105","volume":"105","author":"J Tsai","year":"2008","unstructured":"Tsai, J.  et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041\u20133046 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201383_CR19","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long, G. V.  et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239\u20131246 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201383_CR20","first-page":"391","volume":"6","author":"AM Menzies","year":"2012","unstructured":"Menzies, A. M., Long, G. V. & Murali, R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des. Devel. Ther. 6, 391\u2013405 (2012).","journal-title":"Drug Des. Devel. Ther."},{"key":"BFnrclinonc201383_CR21","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1158\/1535-7163.MCT-11-0989","volume":"11","author":"JG Greger","year":"2012","unstructured":"Greger, J. G.  et al. Combinations of BRAF, MEK, and PI3K\/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11, 909\u2013920 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrclinonc201383_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1158\/1078-0432.CCR-11-1491","volume":"18","author":"JM Kirkwood","year":"2012","unstructured":"Kirkwood, J. M.  et al. Phase II, open-label, randomized trial of the MEK 1\/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555\u2013567 (2012).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201383_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto, P. A.  et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249\u2013256 (2013).","journal-title":"Lancet Oncol."},{"issue":"Suppl.","key":"BFnrclinonc201383_CR24","doi-asserted-by":"publisher","first-page":"LBA8509","DOI":"10.1200\/jco.2012.30.18_suppl.lba8509","volume":"30","author":"C Robert","year":"2012","unstructured":"Robert, C.  et al. METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E\/K mutant advanced or metastatic melanoma (MM) [abstract]. J. Clin. Oncol. 30 (Suppl.), LBA8509 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201383_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T.  et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107\u2013114 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201383_CR26","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","volume":"379","author":"GS Falchook","year":"2012","unstructured":"Falchook, G. S.  et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893\u20131901 (2012).","journal-title":"Lancet"},{"key":"BFnrclinonc201383_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos, P. I.  et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387\u2013390 (2011).","journal-title":"Nature"},{"key":"BFnrclinonc201383_CR28","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian, R.  et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977 (2010).","journal-title":"Nature"},{"key":"BFnrclinonc201383_CR29","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","volume":"29","author":"N Wagle","year":"2011","unstructured":"Wagle, N.  et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085\u20133096 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201383_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/ncomms1727","volume":"3","author":"HB Shi","year":"2012","unstructured":"Shi, H. B.  et al. Melanoma whole-exome sequencing identifies B-V600E-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012).","journal-title":"Nat. Commun."},{"key":"BFnrclinonc201383_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","volume":"22","author":"P Lito","year":"2012","unstructured":"Lito, P.  et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668\u2013682 (2012).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201383_CR32","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T.  et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694\u20131703 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201383_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","volume":"23","author":"R Halaban","year":"2010","unstructured":"Halaban, R.  et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190\u2013200 (2010).","journal-title":"Pigment Cell Melanoma Res."},{"key":"BFnrclinonc201383_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427\u2013430 (2010).","journal-title":"Nature"},{"key":"BFnrclinonc201383_CR35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/onc.2010.408","volume":"30","author":"FM Kaplan","year":"2010","unstructured":"Kaplan, F. M., Shao, Y., Mayberry, M. M. & Aplin, A. E. Hyperactivation of MEK-ERK1\/2 signaling and resistance to apoptosis induced by the ongenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cell lines. Oncogene 30, 366\u2013371 (2010).","journal-title":"Oncogene"},{"key":"BFnrclinonc201383_CR36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrc1097","volume":"3","author":"M Malumbres","year":"2003","unstructured":"Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459\u2013465 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201383_CR37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nrm1498","volume":"5","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell. Biol. 5, 875\u2013885 (2004).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"BFnrclinonc201383_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/383181a0","volume":"383","author":"Z Luo","year":"1996","unstructured":"Luo, Z.  et al. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383, 181\u2013185 (1996).","journal-title":"Nature"},{"key":"BFnrclinonc201383_CR39","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.molcel.2005.10.022","volume":"20","author":"MJ Garnett","year":"2005","unstructured":"Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963\u2013969 (2005).","journal-title":"Mol. Cell"},{"key":"BFnrclinonc201383_CR40","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.cub.2012.03.067","volume":"22","author":"KJ Cho","year":"2012","unstructured":"Cho, K. J.  et al. Raf Inhibitors target ras spatiotemporal dynamics. Curr. Biol. 22, 945\u2013955 (2012).","journal-title":"Curr. Biol."},{"key":"BFnrclinonc201383_CR41","doi-asserted-by":"publisher","first-page":"31429","DOI":"10.1074\/jbc.M802855200","volume":"283","author":"MW Zang","year":"2008","unstructured":"Zang, M. W.  et al. Characterization of Ser338 phosphorylation for Raf-1 activation. J. Biol. Chem. 283, 31429\u201331437 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnrclinonc201383_CR42","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1039\/C2MB25393C","volume":"9","author":"A Baljuls","year":"2013","unstructured":"Baljuls, A., Kholodenko, B. N. & Kolch, W. It takes two to tango--signalling by dimeric Raf kinases. Mol. Biosyst. 9, 551\u2013558 (2013).","journal-title":"Mol. Biosyst."},{"key":"BFnrclinonc201383_CR43","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan, P. T.  et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855\u2013867 (2004).","journal-title":"Cell"},{"key":"BFnrclinonc201383_CR44","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1128\/MCB.26.6.2262-2272.2006","volume":"26","author":"LK Rushworth","year":"2006","unstructured":"Rushworth, L. K., Hindley, A. D., O'Neill, E. & Kolch, W. Regulation and role of Raf-1\/B-Raf heterodimerization. Mol. Cell. Biol. 26, 2262\u20132272 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrclinonc201383_CR45","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn, S. J.  et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209\u2013221 (2010).","journal-title":"Cell"},{"key":"BFnrclinonc201383_CR46","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou, G.  et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431\u2013435 (2010).","journal-title":"Nature"},{"key":"BFnrclinonc201383_CR47","doi-asserted-by":"publisher","first-page":"14903","DOI":"10.1073\/pnas.1008990107","volume":"107","author":"EW Joseph","year":"2010","unstructured":"Joseph, E. W.  et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903\u201314908 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201383_CR48","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nrclinonc.2011.192","volume":"9","author":"DM Keefe","year":"2012","unstructured":"Keefe, D. M. & Bateman, E. H. Tumor control versus adverse events with targeted anticancer therapies. Nat. Rev. Clin. Oncol. 9, 98\u2013109 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc201383_CR49","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","volume":"14","author":"R Anforth","year":"2013","unstructured":"Anforth, R., Fernandez-Penas, P. & Long, G. V. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 14, e11\u2013e18 (2013).","journal-title":"Lancet Oncol."},{"key":"BFnrclinonc201383_CR50","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","volume":"167","author":"RM Anforth","year":"2012","unstructured":"Anforth, R. M.  et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Dermatol. 167, 1153\u20131160 (2012).","journal-title":"Br. J. Dermatol."},{"key":"BFnrclinonc201383_CR51","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","volume":"18","author":"ME Lacouture","year":"2013","unstructured":"Lacouture, M. E.  et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18, 314\u2013322 (2013).","journal-title":"Oncologist"},{"key":"BFnrclinonc201383_CR52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","volume":"60","author":"C Robert","year":"2009","unstructured":"Robert, C., Mateus, C., Spatz, A., Wechsler, J. & Escudier, B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J. Am. Acad. Dermatol. 60, 299\u2013305 (2009).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrclinonc201383_CR53","doi-asserted-by":"publisher","first-page":"e58721","DOI":"10.1371\/journal.pone.0058721","volume":"8","author":"JD Rinderknecht","year":"2013","unstructured":"Rinderknecht, J. D.  et al. RASopathic skin eruptions during vemurafenib therapy. PLoS ONE 8, e58721 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrclinonc201383_CR54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1011-1344(01)00206-8","volume":"63","author":"JL Ravanat","year":"2001","unstructured":"Ravanat, J. L., Douki, T. & Cadet, J. Direct and indirect effects of UV radiation on DNA and its components. J. Photochem. Photobiol. B. 63, 88\u2013102 (2001).","journal-title":"J. Photochem. Photobiol. B."},{"key":"BFnrclinonc201383_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su, F.  et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207\u2013215 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201383_CR56","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","volume":"30","author":"PA Oberholzer","year":"2012","unstructured":"Oberholzer, P. A.  et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316\u2013321 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201383_CR57","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","volume":"30","author":"L Zimmer","year":"2012","unstructured":"Zimmer, L.  et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J. Clin. Oncol. 30, 2375\u20132383 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201383_CR58","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMc1108651","volume":"365","author":"S Dalle","year":"2011","unstructured":"Dalle, S., Poulalhon, N. & Thomas, L. Vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 365, 1448\u20131449 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201383_CR59","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1056\/NEJMoa1208958","volume":"367","author":"MK Callahan","year":"2012","unstructured":"Callahan, M. K.  et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367, 2316\u20132321 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201383_CR60","first-page":"842","volume":"25","author":"M Andrews","year":"2012","unstructured":"Andrews, M.  et al. Colorectal cancer promoted in a patient receiving dabrafenib (GSK2118436) in combination with MEK1\/2 inhibitor trametinib (GSK1120212) [abstract]. Pigment Cell Melanoma Res. 25, 842 (2012).","journal-title":"Pigment Cell Melanoma Res."},{"key":"BFnrclinonc201383_CR61","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1755-148X.2012.00981.x","volume":"25","author":"K Kim","year":"2012","unstructured":"Kim, K.  et al. Significant long-term survival benefit demonstrated with vemurafenib in ongoing phase I study. Pigment Cell Melanoma Res. 25, 866 (2012).","journal-title":"Pigment Cell Melanoma Res."},{"key":"BFnrclinonc201383_CR62","first-page":"847","volume":"25","author":"PB Chapman","year":"2012","unstructured":"Chapman, P. B.  et al. Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res. 25, 847 (2012).","journal-title":"Pigment Cell Melanoma Res."},{"key":"BFnrclinonc201383_CR63","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cgh.2009.05.032","volume":"7","author":"SJ Heitman","year":"2009","unstructured":"Heitman, S. J.  et al. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 7, 1272\u20131278 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrclinonc201383_CR64","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/ajg.2009.139","volume":"104","author":"SW Carmack","year":"2009","unstructured":"Carmack, S. W., Genta, R. M., Schuler, C. M. & Saboorian, M. H. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am. J. Gastroenterol. 104, 1524\u20131532 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrclinonc201383_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrgastro.2009.70","volume":"6","author":"SW Carmack","year":"2009","unstructured":"Carmack, S. W., Genta, R. M., Graham, D. Y. & Lauwers, G. Y. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat. Rev. Gastroenterol. Hepatol. 6, 331\u2013341 (2009).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"BFnrclinonc201383_CR66","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0092-8674(00)81333-1","volume":"87","author":"KW Kinzler","year":"1996","unstructured":"Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159\u2013170 (1996).","journal-title":"Cell"},{"key":"BFnrclinonc201383_CR67","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0959-8049(97)10111-3","volume":"34","author":"U Kressner","year":"1998","unstructured":"Kressner, U.  et al. Ki-ras mutations and prognosis in colorectal cancer. Eur. J. Cancer 34, 518\u2013521 (1998).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc201383_CR68","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/carcin\/bgg009","volume":"24","author":"M Brink","year":"2003","unstructured":"Brink, M.  et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24, 703\u2013710 (2003).","journal-title":"Carcinogenesis"},{"key":"BFnrclinonc201383_CR69","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0092-8674(00)00122-7","volume":"103","author":"M Bienz","year":"2000","unstructured":"Bienz, M. & Clevers, H. Linking colorectal cancer to Wnt signaling. Cell 103, 311\u2013320 (2000).","journal-title":"Cell"},{"key":"BFnrclinonc201383_CR70","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1093\/emboj\/16.13.3797","volume":"16","author":"H Aberle","year":"1997","unstructured":"Aberle, H., Bauer, A., Stappert, J., Kispert, A. & Kemler, R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797\u20133804 (1997).","journal-title":"EMBO J."},{"key":"BFnrclinonc201383_CR71","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/emboj\/17.5.1371","volume":"17","author":"S Ikeda","year":"1998","unstructured":"Ikeda, S.  et al. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 17, 1371\u20131384 (1998).","journal-title":"EMBO J."},{"key":"BFnrclinonc201383_CR72","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nm.2143","volume":"16","author":"SH Lee","year":"2010","unstructured":"Lee, S. H.  et al. ERK activation drives intestinal tumorigenesis in Apcmin\/+ mice. Nat. Med. 16, 665\u2013670 (2010).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201383_CR73","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad, A.  et al. Unresponsiveness of colon cancer to BRAFV600E inhibition through feedback activation of EGFR. Nature 483, 100\u2013103 (2012).","journal-title":"Nature"},{"key":"BFnrclinonc201383_CR74","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke, A. B.  et al. MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 72, 3228\u20133237 (2012).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201383_CR75","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran, R. B.  et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227\u2013235 (2012).","journal-title":"Cancer Discov."},{"key":"BFnrclinonc201383_CR76","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1172\/JCI65780","volume":"123","author":"EV Abel","year":"2013","unstructured":"Abel, E. V.  et al. Melanoma adapts to RAF\/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J. Clin. Invest. 123, 2155\u20132168 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc201383_CR77","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrclinonc201383_CR78","doi-asserted-by":"publisher","unstructured":"Le, K., Blomain, E. & Aplin, A. E. Selective RAF inhibitor impairs ERK1\/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistance melanoma cells. Pigment Cell Melanoma Res. \n                    http:\/\/dx.doi.org\/10.1111\/pcmr.12092\n                    \n                  .","DOI":"10.1111\/pcmr.12092"},{"key":"BFnrclinonc201383_CR79","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1200\/JCO.2011.39.8594","volume":"30","author":"R Anforth","year":"2012","unstructured":"Anforth, R., Blumetti, T. C., Mohd Affandi, A. & Fernandez-Penas, P. Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J. Clin. Oncol. 30, e165\u2013e167 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201383_CR80","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.seminoncol.2012.01.001","volume":"39","author":"MH Lien","year":"2012","unstructured":"Lien, M. H., Fenske, N. A. & Glass, L. F. Advances in the chemoprevention of non-melanoma skin cancer in high-risk organ transplant recipients. Semin. Oncol. 39, 134\u2013138 (2012).","journal-title":"Semin. Oncol."},{"key":"BFnrclinonc201383_CR81","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nrd2397","volume":"6","author":"L Altucci","year":"2007","unstructured":"Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R. & Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6, 793\u2013810 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrclinonc201383_CR82","first-page":"854","volume":"25","author":"H Escuin-Ordinas","year":"2012","unstructured":"Escuin-Ordinas, H.  et al. COX2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Pigment Cell Melanoma Res. 25, 854 (2012).","journal-title":"Pigment Cell Melanoma Res."},{"key":"BFnrclinonc201383_CR83","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1562\/0031-8655(2002)076<0073:CEIMAH>2.0.CO;2","volume":"76","author":"KP An","year":"2002","unstructured":"An, K. P.  et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem. Photobiol. 76, 73\u201380 (2002).","journal-title":"Photochem. Photobiol."},{"key":"BFnrclinonc201383_CR84","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/carcin\/20.10.1939","volume":"20","author":"AP Pentland","year":"1999","unstructured":"Pentland, A. P., Schoggins, J. W., Scott, G. A., Khan, K. N. & Han, R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20, 1939\u20131944 (1999).","journal-title":"Carcinogenesis"},{"key":"BFnrclinonc201383_CR85","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/carcin\/bgs349","volume":"34","author":"EM Burns","year":"2013","unstructured":"Burns, E. M.  et al. Preventative topical diclofenac treatment differentially decreases tumor burden in male and female Skh-1 mice in a model of UVB-induced cutaneous squamous cell carcinoma. Carcinogenesis 34, 370\u2013377 (2013).","journal-title":"Carcinogenesis"},{"key":"BFnrclinonc201383_CR86","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/jnci\/djq442","volume":"102","author":"CA Elmets","year":"2010","unstructured":"Elmets, C. A.  et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J. Natl Cancer Inst. 102, 1835\u20131844 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201383_CR87","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1940-6207.CAPR-08-0206","volume":"2","author":"MM Bertagnolli","year":"2009","unstructured":"Bertagnolli, M. M.  et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev. Res. 2, 310\u2013321 (2009).","journal-title":"Cancer Prev. Res."},{"key":"BFnrclinonc201383_CR88","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11894-011-0218-4","volume":"13","author":"N Arber","year":"2011","unstructured":"Arber, N. & Moshkowitz, M. Small bowel polyposis syndromes. Curr. Gastroenterol. Rep. 13, 435\u2013441 (2011).","journal-title":"Curr. Gastroenterol. Rep."},{"key":"BFnrclinonc201383_CR89","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3","volume":"56","author":"HR Harach","year":"1985","unstructured":"Harach, H. R., Franssila, K. O. & Wasenius, V. M. Occult papillary carcinoma of the thyroid. A \u201cnormal\u201d finding in Finland. A systematic autopsy study. Cancer 56, 531\u2013538 (1985).","journal-title":"Cancer"},{"key":"BFnrclinonc201383_CR90","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11\u201330 (2013).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrclinonc201383_CR91","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1464-410X.2008.07900.x","volume":"103","author":"NB Delongchamps","year":"2009","unstructured":"Delongchamps, N. B., de la Roza, G., Jones, R., Jumbelic, M. & Haas, G. P. Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int. 103, 49\u201354 (2009).","journal-title":"BJU Int."},{"key":"BFnrclinonc201383_CR92","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0002-9440(10)62511-4","volume":"159","author":"G Ling","year":"2001","unstructured":"Ling, G.  et al. Persistent p53 mutations in single cells from normal human skin. Am. J. Pathol. 159, 1247\u20131253 (2001).","journal-title":"Am. J. Pathol."},{"key":"BFnrclinonc201383_CR93","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrclinonc.2012.215","volume":"10","author":"KS Smalley","year":"2013","unstructured":"Smalley, K. S. & Sondak, V. K. Skin cancer: Targeted therapy for melanoma: is double hitting a home run? Nat. Rev. Clin. Oncol. 10, 5\u20136 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrclinonc201383_CR94","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrclinonc201383_CR95","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2005.06.009","volume":"19","author":"Q Ding","year":"2005","unstructured":"Ding, Q.  et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell 19, 159\u2013170 (2005).","journal-title":"Mol. Cell"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.83.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.83","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2013.83.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:24:52Z","timestamp":1684466692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2013.83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,28]]},"references-count":95,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFnrclinonc201383"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2013.83","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,28]]}}}